Gómez-Gil Verónica
Department of Biomedical Sciences (Area of Pharmacology), School of Medicine and Health Sciences, University of Alcalá, 28805 Alcalá de Henares, Madrid, Spain.
Cancers (Basel). 2021 Jan 20;13(3):379. doi: 10.3390/cancers13030379.
Transforming growth factor β (TGFβ) is a pleiotropic cytokine that participates in a wide range of biological functions. The alterations in the expression levels of this factor, or the deregulation of its signaling cascade, can lead to different pathologies, including cancer. A great variety of therapeutic strategies targeting TGFβ, or the members included in its signaling pathway, are currently being researched in cancer treatment. However, the dual role of TGFβ, as a tumor suppressor or a tumor-promoter, together with its crosstalk with other signaling pathways, has hampered the development of safe and effective treatments aimed at halting the cancer progression. This systematic literature review aims to provide insight into the different approaches available to regulate TGFβ and/or the molecules involved in its synthesis, activation, or signaling, as a cancer treatment. The therapeutic strategies most commonly investigated include antisense oligonucleotides, which prevent TGFβ synthesis, to molecules that block the interaction between TGFβ and its signaling receptors, together with inhibitors of the TGFβ signaling cascade-effectors. The effectiveness and possible complications of the different potential therapies available are also discussed.
转化生长因子β(TGFβ)是一种多效性细胞因子,参与多种生物学功能。该因子表达水平的改变或其信号级联的失调可导致包括癌症在内的不同病理状况。目前,癌症治疗领域正在研究多种针对TGFβ或其信号通路中成员的治疗策略。然而,TGFβ作为肿瘤抑制因子或肿瘤促进因子的双重作用,以及它与其他信号通路的相互作用,阻碍了旨在阻止癌症进展的安全有效治疗方法的开发。本系统文献综述旨在深入探讨作为癌症治疗手段调节TGFβ和/或参与其合成、激活或信号传导的分子的不同方法。最常研究的治疗策略包括防止TGFβ合成的反义寡核苷酸、阻断TGFβ与其信号受体之间相互作用的分子,以及TGFβ信号级联效应器的抑制剂。还讨论了不同潜在疗法的有效性和可能的并发症。